Merck Group pays $85M to nab global rights for Abbisko's rare tumor drug after phase 3 win
With the CSF-1R inhibitor space heating up, Merck Group has gone all-in on pimicotinib, paying Abbisko Therapeutics $85 million to secure the global license to the drug.
With the CSF-1R inhibitor space heating up, Merck Group has gone all-in on pimicotinib, paying Abbisko Therapeutics $85 million to secure the global license to the drug.
